Transarterial Chemoembolization With Lipiodol in the Treatment of Initial Unresectable Gastric Cancer (GC)

• Status: Not yet recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective, open-labelled study to evaluate the efficacy and safety of sequential transarterial chemoembolization with lipiodol and neoadjuvant chemotherapy in the treatment of Initial unresectable gastric cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gang Wu

Criteria

Inclusion Criteria:

1. Pathological and imaging diagnosis of gastric adenocarcinoma with initial unresectable R0;

2. Age (18-80 years old) and gender are not limited;

3. No extragastric organ transfer;

4. No serious diseases of the heart, liver, lung, kidney and other organs;

5. Expected survival time > 3 months;

6. Physical performance status score ECOG ≤1 point;

7. Females of reproductive age must have a negative pregnancy test; or male and female patients must agree to use effective contraception during treatment and within 1 year thereafter.

Exclusion Criteria:

1. Poor coagulation function, INR>1.5, or ongoing anticoagulation therapy or known bleeding diseases;

2. WBC <3000/mm3 or platelet count <50000/mm3;

3. AST and/or ALT > 3 times the upper limit of normal;

4. Comorbidities or social environment that can cause subjects to fail to follow the research plan or even endanger patient safety;

5. The patient has other primary tumors.